Additional Relevant Details -- TRUBERZI® first-in-class medication offering sustained relief from multiple symptoms of IBS-D, such as pain, diarrhoea, urgency and bloating(1,2) --
-- Significant step towards bringing the only licensed prescription medication for IBS-D to patients in 28 countries of the European Union(2-4) --
-- Further demonstrates Allergan's commitment to addressing unmet medical needs in gastrointestinal disease by providing innovative medicines for patients and physicians --

TRUBERZI® significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and diarrhoea, with sustained relief demonstrated over six months1,2.  TRUBERZI® was generally well tolerated with the most common side effects being nausea, constipation, and abdominal pain1,2.